BRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo™ And Ata3219

Reuters

21 Jan

BRIEF-<a href="https://laohu8.com/S/ATRA">Atara Biotherapeutics</a> Provides Update On Clinical Programs For Ebvallo™ And Ata3219

Jan 21 (Reuters) - Atara Biotherapeutics Inc ATRA.O:

ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS RELATED TO EBVALLO™ (TABELECLEUCEL) AND ATA3219
ATARA BIOTHERAPEUTICS INC: FDA HAS PLACED A CLINICAL HOLD ON ATARA'S ACTIVE INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATIONS
ATARA BIOTHERAPEUTICS INC: FDA ISSUES CLINICAL HOLD ON EBVALLO™ (TABELECLEUCEL) AND ATA3219 STUDIES LINKED TO EBVALLO COMPLETE RESPONSE LETTER
ATARA BIOTHERAPEUTICS INC: SCREENING AND ENROLLMENT OF NEW PARTICIPANTS IN BOTH PROGRAMS HAVE BEEN PAUSED

Source text: ID:nBw99pdYma

Further company coverage: ATRA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505240792"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505240792\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2505240792?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505240792","market":"us","top_or_hot":-1,"title":"BRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo™ And Ata3219","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Update On Clinical Programs For Ebvallo™ And Ata3219</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS RELATED TO EBVALLO™ (TABELECLEUCEL) AND ATA3219</p></li><li><p>ATARA BIOTHERAPEUTICS INC: FDA HAS PLACED A CLINICAL HOLD ON ATARA'S ACTIVE INVESTIGATIONAL NEW DRUG <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> APPLICATIONS</p></li><li><p>ATARA BIOTHERAPEUTICS INC: FDA ISSUES CLINICAL HOLD ON EBVALLO™ (TABELECLEUCEL) AND ATA3219 STUDIES LINKED TO EBVALLO COMPLETE RESPONSE LETTER</p></li><li><p>ATARA BIOTHERAPEUTICS INC: SCREENING AND ENROLLMENT OF NEW PARTICIPANTS IN BOTH PROGRAMS HAVE BEEN PAUSED</p></li></ul><p>Source text: <span>ID:nBw99pdYma</span></p><p>Further company coverage: <span>ATRA.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo™ And Ata3219</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo™ And Ata3219\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-21 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Update On Clinical Programs For Ebvallo™ And Ata3219</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS RELATED TO EBVALLO™ (TABELECLEUCEL) AND ATA3219</p></li><li><p>ATARA BIOTHERAPEUTICS INC: FDA HAS PLACED A CLINICAL HOLD ON ATARA'S ACTIVE INVESTIGATIONAL NEW DRUG <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> APPLICATIONS</p></li><li><p>ATARA BIOTHERAPEUTICS INC: FDA ISSUES CLINICAL HOLD ON EBVALLO™ (TABELECLEUCEL) AND ATA3219 STUDIES LINKED TO EBVALLO COMPLETE RESPONSE LETTER</p></li><li><p>ATARA BIOTHERAPEUTICS INC: SCREENING AND ENROLLMENT OF NEW PARTICIPANTS IN BOTH PROGRAMS HAVE BEEN PAUSED</p></li></ul><p>Source text: <span>ID:nBw99pdYma</span></p><p>Further company coverage: <span>ATRA.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATRA","symbol_name":"Atara Biotherapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUA7GMXDY:1","article_id":"2505240792","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505240792","pubTimestamp":1737463521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo And Ata3219Jan 21 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATRA":"Atara Biotherapeutics","BK4139":"生物科技"},"translate_title":"简介-Atara Biotherapeutics提供Ebvallo™和Ata3219临床计划的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRA":0.9},"content_text":"BRIEF-Atara Biotherapeutics Provides Update On Clinical Programs For Ebvallo™ And Ata3219Jan 21 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS RELATED TO EBVALLO™ (TABELECLEUCEL) AND ATA3219ATARA BIOTHERAPEUTICS INC: FDA HAS PLACED A CLINICAL HOLD ON ATARA'S ACTIVE INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATIONSATARA BIOTHERAPEUTICS INC: FDA ISSUES CLINICAL HOLD ON EBVALLO™ (TABELECLEUCEL) AND ATA3219 STUDIES LINKED TO EBVALLO COMPLETE RESPONSE LETTERATARA BIOTHERAPEUTICS INC: SCREENING AND ENROLLMENT OF NEW PARTICIPANTS IN BOTH PROGRAMS HAVE BEEN PAUSEDSource text: ID:nBw99pdYmaFurther company coverage: ATRA.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}